Astrazeneca Plc Stock Five Year Return
| ZEG Stock | EUR 128.40 2.75 2.10% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca |
AstraZeneca PLC Company Five Year Return Analysis
AstraZeneca PLC's Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Current AstraZeneca PLC Five Year Return | 4.09 % |
Most of AstraZeneca PLC's fundamental indicators, such as Five Year Return, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
According to the company disclosure, AstraZeneca PLC has a Five Year Return of 4.09%. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Major industry. The five year return for all Germany stocks is notably lower than that of the firm.
AstraZeneca Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in five year return category among its peers.
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 228.75 B | |||
| Shares Outstanding | 1.55 B | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 47.60 % | |||
| Price To Earning | 38.93 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 4.49 X | |||
| Revenue | 44.35 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 9.09 B | |||
| Net Income | 3.29 B | |||
| Cash And Equivalents | 4.96 B | |||
| Cash Per Share | 3.78 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 179.60 % | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | 23.90 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 1.98 X | |||
| Price To Earnings To Growth | 1.37 X | |||
| Number Of Employees | 83.5 K | |||
| Beta | 0.19 | |||
| Market Capitalization | 197.73 B | |||
| Total Asset | 96.48 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 4.09 % | |||
| Net Asset | 96.48 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.